MedDataX Logo

Evaluate the Migration Potential of Xeomin® Compared to Two Other Botulinum Toxin Type A Products

NCT ID: NCT00515944

Last Updated: 2009-04-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-08-31

Study Completion Date

2008-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Xeomin® is a Botulinum neurotoxin type A preparation free of complexing proteins, i.e. free of bacterial proteins other than the active toxin. Injected into the muscle, Xeomin® causes local weakening. Botulinum toxin type A is used for certain neurological and aesthetic treatments. This study will investigate the migration potential of Xeomin®.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Evaluate the Distribution of Botulinum Neurotoxin Type A Administered as Intradermal Injections, Comparing Different Doses, Concentrations, and Delivery Methods

NCT05585398

N/A, as no Specific Medical Condition Will be Treated
COMPLETED PHASE1

Evaluation of BTX Injections in Treatment of Bruxism

NCT05980559

Bruxism
NOT_YET_RECRUITING PHASE3

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines

NCT00430963

Glabellar Frown Lines
COMPLETED PHASE3

Trial Evaluating Xeomin® (incobotulinumtoxinA) for Cervical Dystonia or Blepharospasm in the United States

NCT01287247

Cervical Dystonia Blepharospasm
COMPLETED

Longitudinal Evaluation and Real-world Evidence of NT201

NCT05222607

Glabellar Frown Lines and Canthal Lines and/or Horizontal Forehead Lines in the Upper Face
TERMINATED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conducted in Europe

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Botulinum neurotoxin type A, free of complexing proteins

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy females, 18 to 65 years
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Merz Pharmaceuticals GmbH

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Merz Pharmaceuticals

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Merz Pharmaceuticals

Role: STUDY_CHAIR

Merz Pharmaceuticals GmbH

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Merz Pharmaceuticals GmbH

Frankfurt am Main, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MRZ 60201-0709/1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Muscle Weakness Duration After Single Botulinum Toxin Injection in Masseter
NCT05309564 COMPLETED NA
A Retrospective Chart Review of BOTOX® and Xeomin® for the Management of Cervical Dystonia and Blepharospasm
NCT02245958 COMPLETED
Incobotulinum Toxin A (Xeomin®) As A Treatment For Focal Task-Specific Dystonia Of The Musician's Hand
NCT02107261 COMPLETED PHASE2
Open-Label Non-Inferiority Study Evaluating the Efficacy and Safety of Xeomin® in Subjects With Cervical Dystonia Flex
NCT01486264 COMPLETED PHASE4
Long-term Open-label Study of Botulinumtoxin Type A to Treat Spasticity of Leg(s) or Leg(s) and Arm in Cerebral Palsy
NCT01905683 COMPLETED PHASE3
IncobotulinumtoxinA (Xeomin) for Upper Limb Spasticity
NCT00465738 COMPLETED PHASE3
Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Leg(s) in Cerebral Palsy
NCT01893411 COMPLETED PHASE3
A Retrospective Chart Review of BOTOX® and Xeomin® for the Treatment of Cervical Dystonia and Blepharospasm
NCT01814774 COMPLETED
Kinematic-based BoNT-A Injections for Bilateral ET
NCT02551848 UNKNOWN PHASE2
A Comparative Study to Evaluate the Effects and Mechanism of Action of Dysport®, Botox® and Xeomin® in the Extensor Digitorum Brevis Model in Healthy Adult Male Participants
NCT04970407 COMPLETED PHASE1
Treatment of Notalgia Paresthetica With Xeomin
NCT01098019 COMPLETED PHASE3
NT 201 (Xeomin®/Bocouture®) in Comparison With Clostridium Botulinum Toxin Type A in the Treatment of Glabellar Frown Lines
NCT00777803 COMPLETED PHASE3
Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy
NCT02002884 COMPLETED PHASE3
Pharmacodynamic and Safety of MT10107(Botulinum Type A Neurotoxin) in Comparison to BOTOX®
NCT03796351 COMPLETED PHASE1
Clinical Trial to Assess Efficacy, Safety and Tolerability of Botulinum Toxin A (Xeomin®) in Treatment of Expression Wrinkles in the Upper Third of the Face
NCT00986570 COMPLETED PHASE3
Bruxism Xeomin® Intervention Trial
NCT04792398 UNKNOWN PHASE4
Safety and Efficacy of Two Types of Botulinum Toxin Type A For the Treatment of Glabellar Lines
NCT01271452 COMPLETED PHASE4
Investigation of Efficacy of incobotulinumtoxinA (Xeomin) in Relieving Symptoms of Restless Leg Syndrome.
NCT01931878 COMPLETED PHASE2
A Pilot Study Testing Onabotulinum Toxin A Versus Incobotulinum Toxin A Injections for Facial Wrinkles
NCT02019004 ACTIVE_NOT_RECRUITING EARLY_PHASE1
The Effect of Vocal Rest Versus Vocalization Following Xeomin® Injections in Spasmodic Dysphonia
NCT03129087 UNKNOWN NA
Safety and Efficacy of NT 201, Free of Complexing Proteins, in the Treatment of Glabellar Frown Lines
NCT00694148 COMPLETED PHASE3
Botulinum Toxin Type A for Neuroma Pain
NCT01374191 WITHDRAWN PHASE2
DEgenerative ROtator Cuff Disease and Botulinum TOXin
NCT05327972 RECRUITING PHASE2
Partial Blocks of Rectus Femoris and Soleus With Botulinum Toxin Type A (Xeomin®) to Improve Gait in Hemiparesis
NCT03119948 UNKNOWN PHASE2
Treatment of Temporo-Myofascial Disorder of Muscular Origin Using Botulinum Toxin: A Prospective Study
NCT02810015 UNKNOWN PHASE2